PATENT CLAIM ANALYSIS

Application Number: 16127375
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "263300"]

Abstract:
Methods and compositions for treating narcolepsy are provided which include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with narcolepsy. Also provided are methods and compositions for treating narcolepsy which include administering to a patient in need thereof gaboxadol or a pharmaceutically acceptable salt thereof, in combination with one or more of a CNS stimulant, a eugeroic agent, an antidepressant or a GABA B  receptor agonist.

Claim (Index 8):
The method of  claim 7 , wherein the CNS stimulant is selected from the group consisting of amphetamine, dextroamphetamine, methamphetamine, methylphenidate, phentermine, diethylpropion, phendimetrazine, lisdexamfetamine, benzphetamine, atomoxetine, caffeine and ephedrine.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 97.0
- Lexical Diversity: 1.78571
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15191068', '16056754', '15873425', '15185650', '15433660']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7763822270963122
- 35 USC 102 Novelty (BERT): 0.5278146956149479
- Combined Prediction Score: 0.7515254739481758
- Mean Citation Score: 295.706942
- Max Citation Score: 304.12854
- Similarity Product: 182.65137252716303

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test